NTRK1 and cancer: As EGFR or growth signaling tyrosine receptor kinases are located in the cellular membrane (16, 18), we hypothesized that TKIs, including crizotinib, participate in modifying the P-gp activity in the membranes of drug-resistant cancer cells.